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The phenotype of mice lacking the delta isoform of
protein kinase C reveals that this isoform curtails
signaling events after engagement of the antigen-
specific receptor on B cells. The result is a state of
non-responsiveness, termed anergy, that represents
one form of immunological self-tolerance.
Protein kinase C (PKC) is one of the cell’s most impor-
tant signal-transducing molecules, responding to a
diversity of extracellular cues to regulate a number of
central processes, including proliferation, metabolism,
migration and death [1]. It is also one of the more
complex signal transducers, constituting a family of
serine/threonine kinases that can phosphorylate a
multitude of cellular substrates. The family currently
includes 12 isoforms, which are structurally related
and have been grouped into 3 classes according to
whether or not they require diacylglycerol (DAG)
and/or Ca2+ for activation. The various isoforms have
different cell-type distributions, and show differential
compartmentalizations within cells upon activation.
More confounding, a single isoform can have distinct,
even opposing, functions in different cell types. It has
been a major challenge to penetrate this complexity in
order to attribute to specific isoforms specific func-
tions in specific cell types. Fortunately, some key
advances have come in the past few years thanks to
the development of transgenic mouse lines over-
expressing a particular PKC isoform, knockout mouse
lines lacking a single isoform, and molecule-specific
inhibitors. A good example is provided by two recent
papers that reported an important role for PKCδ in tol-
erance induction in B lymphocytes [2,3].
PKC activation appears to influence multiple facets
of immune system function, from T and B lymphocyte
differentiation to various forms of leukocyte activation.
Mice overexpressing PKCα in T lymphocytes exhib-
ited decreased T-cell proliferative responses, a biased
pattern of T-cell cytokine secretion and reduced pro-
duction of antibodies by B cells [4]. Mice lacking
PKCβ showed reduced B-cell proliferative responses
and impaired humoral immunity [5]. Since these two
molecules belong to the ‘classical’ class of isoforms,
which requires both DAG and Ca2+ for activation,
investigations into PKC activities focused for some
time on immune system functions that depend on
both of these intracellular mediators. However, recent
reports [2,3,6] of T- and B-cell abnormalities in mice
lacking PKCθ and PKCδ, respectively, have changed
this emphasis because these kinases are both of the
‘novel’ class of isoforms, whose activation requires
DAG but not Ca2+. Several observations have piqued
interest in examining the role of PKCδ in the immune
system. For example, this isoform has the unusual
property of being tyrosine phosphorylated [7], and this
phosphorylation event takes place within a minute of
engagement of the surface immunoglobulin (Ig) recep-
tors on B cells [8,9]. In addition, this isoform can have
a potent negative influence on cell behavior, inhibiting
proliferation and enhancing death [7].
When PKCδ-deficient mice were screened for
immune system manifestations, the most overt abnor-
malities were splenomegaly and lymphadenopathy,
both attributed to an increase in the number of B cells
of the conventional, B2, type. This augmentation was
not observed in the bone marrow, indicating that it is
a post-maturation phenomenon. Abnormal B-cell
accumulation was also revealed by the unusually high
numbers of germinal centers in the spleen and lymph
nodes in the absence of intentional antigenic stimula-
tion. Interestingly, smooth muscle cells from these
knockout mice were previously reported to show
aberrant homeostasis, but the mechanism appeared
to differ from that for B cells: a normal proliferative
capacity [3] and decreased propensity for cell death
[2,3] for the former; increased proliferation and normal
death for the latter [10]. The B-cell abnormalities in
PKCδ-deficient mice had pathological consequences.
Concentrations of serum IgG1 and IgA were increased,
and auto-antibodies recognizing a variety of auto-anti-
gens could be detected after 6 months of age. Igs
were aberrantly deposited in the kidneys, and B-cell
infiltrates were found in perivascular regions of multi-
ple organs. Clearly, then, B-cell tolerance to self-anti-
gens was somehow compromised.
To explore the mechanisms underlying the loss of
B-cell tolerance in mice lacking PKCδ, Mecklen-
brauker et al. [2] introduced the knockout mutation
into a well-studied transgenic mouse system focused
on Igs reactive to hen egg lysozyme (HEL). Single-
transgenic mice (IgHEL) that carry pre-rearranged Ig
genes encoding the heavy and light chains of an anti-
body that recognizes HEL develop a B-lymphocyte
repertoire highly skewed for HEL-reactive cells, and
produce large amounts of anti-HEL antibodies upon
antigenic stimulation [11]. Double-transgenic mice
(IgHEL/mHEL) that also harbor a second transgene
encoding a membrane-bound form of HEL as a self-
antigen lack mature HEL-responsive B cells because
these cells are deleted during maturation in the bone
marrow [12]. If, instead, the second transgene (sHEL
in IgHEL/sHEL mice) encodes a soluble form of HEL
as the self-antigen, significant numbers of mature
HEL-reactive B cells are generated, but these do not
produce anti-HEL antibodies because they have been
rendered non-responsive, or anergic [11]. This has
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proven a very powerful system for probing the signal-
ing pathways implicated in anergy induction [13–17].
The current picture, schematized in Figure 1, is that
the anergic B lymphocytes from IgHEL/sHEL mice are
in an activated state compared with antigen-naïve 
B cells from IgHEL mice, but that the activation is
incomplete in comparison with that of antigen-stimu-
lated B cells from IgHEL animals. The aborted activa-
tion involves low calcium oscillations, muted protein
tyrosine phosphorylation, and mobilization of the tran-
scription factor NFAT and the MAP kinase ERK; but it
stops short of a typical biphasic calcium response, a
standard pattern of protein tyrosine phosphorylation,
and additional mobilization of the NF-κB transcription
factor and the MAP kinase JNK [13,15,16]. The ulti-
mate result is a negative response: lack of prolifera-
tion, reduction in survival, blockade of differentiation,
and a failure to express T-cell co-stimulatory mol-
ecules [13,14], reflecting induction of genes which
encode negative regulators of signaling and transcrip-
tion but not genes promoting proliferation [17]. Where
does PKCδ come in?
Breeding of the PKCδ knockout mutation into double-
transgenic IgHEL/mHEL mice had no overt effect: as
usual, potentially auto-reactive HEL-responsive B cells
were deleted in the bone marrow. However, introduc-
tion of the mutation into IgHEL/sHEL animals showed
a striking influence: HEL-reactive B cells emerged into
the periphery as usual, but they were no longer toler-
ant to HEL, no longer anergic. These animals had sig-
nificant titers of anti-HEL antibodies in the serum, and
their B cells resembled those of non-transgenic or
IgHEL mice in many features of their behavior, culmi-
nating in a normal response to HEL. Thus, chronic
exposure of PKCδ-deficient B cells to self-antigen
stimulation failed to induce tolerance, via anergy, as it
does for wild-type B cells; in marked contrast, acute
exposure to the same antigen was perfectly capable
of eliciting immunity.
The search is now on for the molecular basis of the
B-lymphocyte abnormalities exhibited by PKCδ-defi-
cient mice. One group [3] observed an augmentation of
interleukin-6 production upon engagement of surface
Ig (and the costimulatory molecule CD40), attributed to
an increase in the transcription factor NF-IL6. This
seems an attractive explanation for at least some of
the B-cell aberrancies because mice lacking PKCδ and
transgenic mice overexpressing IL-6 exhibit a number
of similarities. The other group [2] focused on the tran-
scription factor NF-κB, no doubt prompted by a previ-
ous report [15] that this factor is not activated in
anergic B cells, neither ex vivo nor after cognate
antigen stimulation in vitro. This lack of activity is due
to reduced nuclear translocation of NF-κB, a reflection
of inefficient degradation of an inhibitor that seques-
ters it in the cytoplasm, IκB. Indeed, the non-anergic B
cells from IgHEL/sHEL mice lacking PKCδ showed
enhanced NF-κB activation, greater than that of anergic
B cells from double-transgenic animals expressing
PKCδ, both with and without exogenous HEL stimula-
tion, and even greater than that of non-anergic B cells
from IgHEL animals, whether or not they expressed
PKCδ. Rather surprisingly, degradation of IκB was 
not diminished in parallel with enhanced activation of
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Figure 1. Different signals emanating
from the B cell antigen receptor.
Left, events downstream of an activation
stimulus (e.g. a foreign antigen). Right,
events downstream of a tolerogenic stim-
ulus (such as a soluble self-antigen). The
upper curve represents the plasma mem-
brane, and the inner represents the
nuclear membrane. Ca2+ depicts the
calcium signal, with the size of the triangle
reflecting the strength and duration of this
signal. ERK, extracellular signal regulated
kinase; JNK, c-Jun N-terminal kinase;
NFAT, nuclear factor of activated T cells;



































NF-κB, suggesting that there might be an alternative
route to boost activation. The differences in NF-κB
behavior in the presence and absence of PKCδ were a
property of the anergic state, as they were not observed
with B cells from either non-transgenic or IgHEL mice.
These new findings pointing to a ‘braking’ role for
PKCδ during anergy induction in B cells are of signifi-
cant interest from a number of perspectives. Firstly,
they pose again the question, in a perfectly matched
setting, of how the same signal transducer can have
divergent effects in two cell types: increased prolifer-
ation [3], normal death [2,3] in B cells; and normal pro-
liferation, increased death in smooth muscle cells [10].
The answer must await painstaking dissection of the
sequence of events downstream of PKCδ activation in
the two cell types. Secondly, these studies raise the
issue of what transducer might have an analogous
function in T cells, which also undergo anergy induc-
tion when confronted with a self-antigen under the
appropriate circumstances. In fact, there are similari-
ties in the activation state of anergic T and B cells,
notably normal NFAT [15,18] but defective NF-κB
[15,19] activation. No T-cell abnormalities were
observed in the PKCδ-deficient mice. PKCθ has a
number of features in common with PKCδ, such as not
requiring Ca2+ for activation and perhaps being more
dependent on phosphatidylinositol 3-kinase than DAG
as an upstream regulator [8,20]. The results on PKCθ
knockout mice argue for this isoform having a positive
role in the T-cell response, however, being essential
for activation of mature T cells through the antigen
receptor [6]. It is imperative now to look elsewhere.
Finally, one cannot help but evoke the potential of
PKCδ-specific modulators to prevent or reverse B-
cell-mediated autoimmune diseases, in particular sys-
temic lupus erythematosus.
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